Streetbeat News

Analyst Ratings

VRA

Small Cap Consumer Research analyst Eric Beder has reiterated a Buy rating on Vera Bradley (NASDAQ:VRA) and maintained a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:33 am

AAPL

AMD

CRM

DELL

IBM

MSFT

NOW

NVDA

ORCL

PLTR

QQQ

XLK

Wedbush analyst Daniel Ives suggests that tech stocks are poised for growth as the Federal Reserve begins a rate-cutting cycle. Key players in the AI revolution, such as Nvidia and Microsoft, are expected to drive this growth, with other tech companies like Oracle, ServiceNow, Palantir, Salesforce, Dell, IBM, Apple, and AMD joining the trend. The Invesco QQQ Trust and Technology Select Sector SPDR Fund have shown positive performance, indicating investor optimism despite high valuations.

Portfolio Pulse from Shanthi Rexaline

September 16, 2024 | 6:25 am

MRK

MRNA

Moderna Inc (NASDAQ:MRNA) announced a reduction in R&D spending and a focus on ten prioritized products, aiming for ten product approvals in three years. Analysts have downgraded the stock, citing delayed profitability and challenges in the respiratory vaccine market. The stock closed lower by 2.01%.

Portfolio Pulse from Vandana Singh

September 13, 2024 | 10:34 pm

APLS

Analysts have provided 15 ratings for Apellis Pharmaceuticals (NASDAQ:APLS) over the past three months, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has decreased by 3.52% to $78.47. Analysts have adjusted their ratings and price targets based on recent developments, reflecting a cautious outlook. Apellis has shown strong revenue growth but faces challenges with profitability and debt management.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 9:01 pm

MRNA

16 analysts have recently evaluated Moderna (NASDAQ:MRNA), showing a mix of bullish and bearish perspectives. The average 12-month price target has decreased by 18.06% to $111.5. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Moderna faces challenges with revenue growth, net margin, ROE, and ROA, but maintains a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 9:00 pm

FTNT

Fortinet (NASDAQ:FTNT) has received 20 analyst ratings in the last three months, with a mix of bullish and neutral sentiments. The average 12-month price target has increased to $71.85, reflecting a 3.58% rise. Analysts have adjusted their ratings and price targets, indicating a positive outlook for Fortinet. The company shows strong financial performance with high net margins and ROE, but faces challenges in debt management.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 9:00 pm

Citigroup analyst Steven Zaccone maintains a Buy rating on RH and raises the price target from $340 to $355.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 8:55 pm

AAPL

The options market shows a mixed sentiment towards Apple (AAPL), with a slight bearish tilt. Despite this, analysts maintain strong buy ratings with high price targets. The current stock price is $222.41, with a neutral RSI. Next earnings are expected in 48 days.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 8:39 pm

ELME

Wells Fargo analyst Blaine Heck has maintained an Equal-Weight rating on Elme (NYSE:ELME) and raised the price target from $14 to $17.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 8:25 pm

MCK

Wells Fargo analyst Stephen Baxter has maintained an Equal-Weight rating on McKesson (NYSE:MCK) but has lowered the price target from $576 to $535.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 8:23 pm